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ABSTRACT 
S-adenosyl methionine (SAM) is the sole methyl donor for all biological reactions in 
humans. Folate consumption, required for SAM generation, is also essential for 
dTMP synthesis and both events occur via enzymes of the one-carbon pathway. 
Frequently occurring alleles of these enzymes have occasionally been associated 
with several diseases including cancer. However, the cumulative effects of the 
polymorphic variants of these enzymes on S-adenosylmethionine production have 
not been studied. The identification of a biomarker that can reflect the collective 
effect of these allelic variants is critical in moving the field forwards. We 
hypothesized that Cancer-Testis (CT) genes, whose expression strongly correlates 
with DNA hypomethylation, could be such a biomarker. In this study, we have 
pursued an extensive correlation of CT expression and allelic variants of the several 
one-carbon pathway enzyme genes , including methyltetrahydrofolatereductase 
(MTHFR), methionine synthase (MS), reduced folate carrier (RFC) and methionine 
synthase reductase (MTRR) in non-small cell lung cancer. Our results revealed 
linkage disequilibrium among alleles as well as correlations between given 
genootypes and CT gene expression, and illuminate the critical next steps that need 
to be pursued. 
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ÖZET 
İnsanlarda bütün biyolojik tepkimelerde kullanılan tek metil grubu vericisi S-
adenozilmetiyonin (SAM)’dir. SAM üretimi için gereken folik asit tüketimi, 
deoksitimidin monofosfat (dTMP) sentezi için gereklidir ve her iki olay da bir 
karbon metabolik yolundaki enzimler sayesinde gerçekleşir. Bu enzimlerde sıkça 
görülen aleller kanser dâhil birçok hastalık ile ilişkilendirilmiştir. Ancak, bu 
enzimlerde görülen polimorfizmlerin SAM üretimine olan kümülatif etkisi şu ana 
kadar çalışılmamıştır. Bir karbon metabolik yolundaki enzim alellerinin kümülatif 
etkisine duyarlı ve buna cevap verebilecek biyolojik bir belirleyicinin teşhisi, bu 
alanda ilerleme kaydedilmesi için önemlidir. Hipotezimize göre transkripsiyonları 
DNA demtilasyonu ile ilişkili olan Kanser-Testis (KT) genleri, böyle bir biyolojik 
belirteç olabilir. Bu çalışmada, küçük hücre dışı akciğer kanserinde (KHDAK) KT 
gen ifadesi ile bir karbon metabolik yolundaki, metilentetrahidrofolat redüktaz 
(MTHFR), metiyonin sentaz (MS), indirgenmiş folat taşıyıcısı (RFC) ve metiyonin 
sentaz redüktaz (MTRR) enzim alelleri ilişkiyi araştırdık. Sonuçlarımız, enzim 
alelleri arasında linkage disequilibrium olduğunu göstermiş, ayrıca belli bir haplotip 
ile CT gen ifadesi arasındaki ilişkiyi açığa çıkarmış ve izlenecek adımlarda önemli 
noktaları aydınlatmıştır. 
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CHAPTER1. INTRODUCTION 
1.1 DNA methylation 
The inheritance of information which is not based on DNA sequence is known as 
epigenetics [1]. DNA methylation is a crucial determinant in gene expression, DNA stability and 
chromatin modifications. The vitality of DNA methylation for vertebrates has not only been 
shown in embryonic lethality of DNA methyl transferase-1 (DNMT1) knockout mice, but also 
by its deregulation in various diseases, especially cancer [2]. DNA methylation is thought to be 
evolved to silence viral sequences and transposable elements as well as to regulate gene 
transcription [3]. DNA methylation is a heritable, tissue and cell specific modification of 
cytosine residues in CpG sequences.  The methyl group can be attached at the N4 or C5 positions 
of the cytosine residues of prokaryotic or eukaryotic genomic DNA [4]. The distribution of the 
CpG residues in the genome is not equal, some regions such as the Alu repeats and transcription 
start sites contain a higher frequency of CpG residues than other regions [84].  
Most of the mammalian genome consists of extended regions that are deficient for 
CpG’s. CpG residues are at 20% of their predicted frequency in the mammalian genome. This is 
thought to be a direct consequence of an increased mutation rate of the 5-methylcytosine residues 
found in CpG sequences from cytosine to thymine. Most methylated CpG’s are found in clusters, 
called a CpG island which corresponds to 1% of the human genome. The term CpG island refers 
to a 500 base pair window with an increased G:C content of at least 55%, and an observed to 
expected CpG frequency of at least 0.65.  These islands may span the 5’ regions of 
approximately half of the human genes including exons, promoters and untranslated regions.  
Up to 80% of all cytosine residues, which are not related to CpG islands, are normally 
methylated. In contrast, the CpG residues in CpG islands, especially at the gene promoter regions 
of actively transcribed genes, are usually unmethylated.  The major genomic regions which have 
methylated CpG islands are the inactive X chromosome in female and silenced alleles of 
parentally imprinted genes [5]. The CpG methylation also occurs at the sites with a low 
frequency of CpG’s such as repeat DNA sites, heterochromatin, telomeres, non-coding regions 
and exons. Methylation of the “bulk” of the genome enables the silencing of these non-coding 
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regions, which prevents the transcription of repeat elements and parasitic DNA sequences. DNA 
methylation has also attracted a considerable interest in the cell differentiation and tissue specific 
gene expression process [6]. 
DNA methylation is a dynamic process in which involves DNA methyltransferases 
(Dnmt1, Dnmt3a and Dnmt3b), methyl-binding proteins, histone modifying enzymes, chromatin 
remodeling factors and their molecular complexes [84]. It has been previously shown that 
cyclical and dynamic methylation/demetylation of the CpG residues in a model containing the 
ps2 gene promoter occurs with the presence of MeCP2 (a methyl-binding protein), SWI/SNF (a 
histone remodeling complex), DNMT1 and DNMT3a and DNMT3b [7]. DNMT1 is responsible 
for the maintenance methylation of the genome after each round of replication. During the 
replication of eukaryotic genomic DNA, approximately 40 million CpG dinucleotides are 
converted into the hemimethylated state in the newly synthesized DNA strand. These 
hemimethylated CpG sites must be methylated precisely to maintain the original DNA 
methylation pattern. DNMT1 is located at the replication fork and methylates newly 
biosynthesized DNA strands directly after the replication. DNMT3a and DNMT3b 
methyltransferases methylate CpG dinucleotides without preference for hemimethylated DNA, 
and are responsible for the de novo methylation of DNA [8].  
 
 
1.2 DNA Methylation and Cancer 
For over a decade, abnormalities of DNA methylation in cancer cells have been 
recognized [9]. In cancer, the usual pattern of methylation is observed to be genomic 
hypomethylation and gene-specific hypermethylation.  Hypermethylation, which is also related 
to transcriptional silencing, is a common mechanism for the inactivation of several tumor 
suppressor genes in cancer [10]. Methylations of such genes seem to occur early in 
carcinogenesis, and in some cases increasing progressively leading to malignant phenotypes 
[11]. Hypermethylation occurs not only at the promoter of tumor suppressor genes, but also at 
the promoter regions of other genes involved in cancer progression such as DNA repair, cell 
cycle regulation, apoptosis, hormonal response and cell adherence genes [12]. Previously, it has 
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been suggested that a tumor-type specific profile of DNA hypermethylation exists and thus 
allows us to use these hypermethylated loci as biomarkers of tumorigenesis [13], [11].  
On the other hand, global DNA hypomethylation is also seen in early carcinogenesis [14]. 
It has been previously shown that DNA hypomethylation causes genomic instability, thus 
resulting in increased levels of DNA damage, mutation rates, copy number alterationd and loss of 
heterozygosity. Chen et al have shown that hypomethylation in murine embryonic stem cells 
lacking Dnmt1, at the same time significantly elevating mutation rates in two model genes [15]. It 
has been suggested that there is a direct correlation between the methylation capacity of the cell 
and genetic instability [16]. Abnormal DNA methylation has been associated with tumor 
aggressiveness and poor prognosis [17]. Precancerous cells showing aberrant DNA methylation 
profiles designate increased malignancy [18]. The reason for the instability of genomic DNA 
observed along DNAhypomethylation might be the lack of a splice variant of Dnmt3b which 
results in chromosomal instability through hypomethylation of pericentromeric satellite regions 
[19]. In addition, Dnmt1 over-expression observed in cancer cells has been observed to associate 
with increased CpG island methylation in a cancer-specific manner [19]. 
 In normal cells, DNA methylation allows the condensation of the chromatin structure 
through the recruitment of the chromatin-organizing proteins such as histone remodeling 
complexes or polycomb group proteins [20]. In a DNA-hypomethylated cell, this arrangement is 
lost which results in chromatin decondensation and chromosomal rearrangements [21].  
 
1.3 Cancer Testis (CT) Genes 
 CT genes are a group of genes which are consistently expressed in spermatogonia, 
oogonia and trophoblast cells, but not expressed in any other healthy tissues except cancer cells 
[22]. CT genes can be categorized as families based on sequence similary. Some families such as 
MAGE-A and SSX contain more than 8 members, while others like NY-ESO-1 consist of only 
two. As will be explained below, despite the dissimilarity of their sequences, there is 
overwhelming evidence that tumor-specific aberrant CT gene expression occurs in a coordinate 
fashion. More than half of 40 CT genes, so far identified, are located on the X chromosome 
[22],[23]. CT gene promoters (NY-ESO-1, MAGE-A1, SSX4 and SSX 7) lack a TATA box 
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[24], {unpublished data}. An interesting aspect of CT genes is that most of them are thought to 
have risen due to duplications [23] and thus, they are located  juxtameric to each other forming 
gene clusters.  
1.3.1 CT Gene Expression Regulation 
Since CT genes are diverse, sequence-wise, it can be envisioned that they are possibly 
regulated via unique transcription factors. Yet, the fact that all CT genes, studied to date, are co-
expressed, suggests the presence of a general mechanism behind their expression in cancer. DNA 
methylation is thought to be the major control mechanism for the expression and silencing of CT 
genes. This assumption was previously verified by a detailed analysis of the CpG islands of a 
model CT gene, MAGEA1 [24]. It has been shown that the critical CpG islands at the promoter 
region remain significantly methylated in vivo where the gene is not expressed [24]. Similary, 
expression of all other CT genes, studied to date, correlates with the demethylation of their 
promoter-proximal DNA regions [24](our unpublished data). 
An example to such an experiment is detailed below SSX expression correlates with its 
methylation status. The southern blot figure below shows the change in expression of SSX genes, 
along with their methylation status (Figure 1). The general demethylation observed for the SSX 
gene region seems to occur in parallel to L1 repeat demetylation, which in turn, is considered to 
reflect the general methylation state of the genome.   
The probes used in the assay were SSX 1, 2, 3, 4 and 5 (a mixture of SSX genes) and L1. 
SSX probe recognizes all of the SSX exons whereas L1 probe recognizes all of the L1 repeat 
sites. In this experiment, the genomic DNA from different cancer cell lines was cleaved by MspI 
and HspII enzymes. Then, the digested products were separated by agarose gel electrophoresis. 
Following the transfer of the DNA to the nitrocellulose membrane, the membrane wass exposed 
to a hybridization probe, a single DNA fragment with a specific sequence whose presence in the 
target DNA is to be determined. Then by autoradiography, the pattern of hybridization was 
visualized.  
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Both MspI and HspII cut at CCGG, yet MspI enzyme cuts DNA regardless of the 
methylation status while HspII cuts only the unmethylated DNA. Thus, the methylated SSX or 
L1 sequence will not be digested by HspII, as seen for the Calu-3 cell line.  On the other hand, 
the unmethylated SSX or L1 sequences will be digested by HspII and, as observed for the SK-
LC17 cell line. . In fact, for this cell line, the digestion pattern observed for the two enzymes is 
identical suggesting complete demetylation of SSX gene proximal CCGG sites. Below the 
southern blot figure, semi-quantitative PCR results show that the expression of SSX genes 
increase in parallel to the decrease of methylation within the SSX , as well as in L1 genomic 
DNA. 
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Figure 1. Southern blot and PCR showing the expression levels along with their methylation status of SSX genes 
and L1 repeats. Probes:  SSX1 and L1. M: Msp1, H: HspII 
 
 Thus, there are many examples demonstrating a clear relationship between 
hypomethylation of genomic DNA and CT gene induction in cancer. CT genes can be 
upregulated by DNA methyl transferase inhibitors [25] and histone deacetylase inhibitors as well 
[22]. In 2005, Gure et al reported that in NSCLC (non-small cell lung cancer), CT gene 
expression is frequently observed. In the same study, CT genes were found to be coordinately 
expressed. Among 9 CT genes studied, expression of every single CT was found to correlate 
significantly with any other [26].  
Moreover, CT genes were found to be significantly associated with less differentiated, 
higher grade of tumors, later stages of cancer and worse outcome. Larger tumor size and 
invasion capacity are also correlated with CT expression [26]. It was also observed that  CT 
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expression increases as the tumors progress [26]. Therefore, one can presume that the 
hypomethylation observed in cancer cells causes demethylation in the promoter regions of CT 
genes, thus increasing their expression. . Most importantly, in the same study, overall survival of 
patients without (or with low levels of) CT gene expression was found to be significantly better 
than those with high level CT gene expression in their tumors. Thus, given this relationship, if 
the CT expression levels of tumors can be decreased, it can be hypothesized that this would 
result in improved survival. In this study, I have addressed this question with reference to the 
one-carbon pathway. 
 
1.4 S-Adenosylmethionine: The universal methyl donor 
S-adenosylmethionine (SAM) is a coenzyme involved in methyl group transfers. It is 
synthesized from ATP and methionine by methionine adenosyltransferase. In this reaction, the 
tri-phosphate group is cleaved from ATP and methionine is covalently attached. Figure 2 shows 
the chemical structure of SAM.  
 
 
Figure 2.The chemical structure of S-adenosylmethionine. The methyl group attached to the sulfur atom is 
reactive and is donated to an acceptor, forming S-adenosylhomocysteine., adapted from [27]. 
 
The methyl group attached to the sulfur atom is chemically reactive and thus allows the 
donation of this methyl group to an acceptor substrate in the methylation reactions. The product 
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following these transmethylation reactions, is S-adenosylhomocysteine (SAH) is formed by the 
demethylation of SAM.  
Since SAM is the only methyl donor in the cell, the efficiency of SAM production might 
possibly effect methylation reactions including DNA and histone methylation. A recent study 
showed that rats fed with a methyl-deficient diet displayed significantly reduced levels of SAM, 
reduced ratios of SAM to SAH (SAM’s more stable metabolite) and that this correlated with 
elevated levels of DNA hypomethylation [28]. Since CT gene expression is controlled by DNA 
methylation, a deficiency in SAM production could in turn be crucial in the  regulation of CT 
genes. The low production of SAM might result in DNA hypomethylation, causing CT up-
regulation and poor prognosis in cancer. For this reason, we have focused on the one carbon 
pathway in order to investigate the possible mechanisms which consequently results in reduced 
SAM production and DNA hypomethylation.   
 
1.5 One carbon pathway 
 One carbon metabolism is an intervention of two pathways enabling the cross-talk 
between epigenetic and genetic processes, which involves DNA methylation and DNA synthesis. 
One carbon metabolism is vitally important for the maintenance of methionine cycle, nucleotide 
synthesis and biological methylation reactions.  Folate is the most important input substrate 
utilized in the one carbon pathway. Folate is not only an essential co-factor for the de novo 
biosynthesis of purines and pyrimidines, it also plays an important role in DNA synthesis, 
stability and integrity [29]. Figure 3 summarizes those particular events in the one carbon 
pathway which we chose to focus on. 
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Figure 3. The one carbon pathway. Annotations: MTHFR- Methylenetetrahydrofolate reductase, MTRR-
Methionine synthase reductase, MTR- Methionine synthase, RFC- Reduced Folate Carrier, TS- Thymidylate 
synthase, DHF- Dihydrofolate, THF-Tetrahydrofolate, SAM- S-adenosylmethionine, SAH- S-
adenosylhomocysteine, Hcy- homocysteine 
 
 Folate may be gathered from two sources; either from foods or from blood by serum folate. 
Because folate cannot pass through the cell membrane when its glutamate tail is longer than 3, it is 
absorbed in the small intestine after the hydrolysis of polyglutamate chain by glutamate 
carboxypeptidase II (GCPII) [30]. Two receptors can transport folate from blood to into the cells. 
The folate receptor (FR), and the reduced folate carrier (RFC). The FR has a higher affinity for 
oxidized folate when compared to RFC. When taken into the cell, folate is first converted to 
dihydrofolate, and then to tetrahydrofolate (THF) by the enzyme dihydrofolate reductase (DHFR).  
The following reaction generates the origin of one carbon units by the breakage of β-carbon of 
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serine. In this reaction catalayzed by serine hydroxymethyltransferase (SHMT), THF is converted to 
N5-N10-methylene-THF while glycine is produced. N5-N10-methylene-THF is a crucial intermediate 
factor for the direction of the pathway [30].  
For thymidine synthesis, deoxythymidylate monophosphate (dTMP) is synthesized from 
deoxyuridylate monophophate (dUMP) by thymidylate synthase (TS). TS transfers a methyl group 
from N5-N10-methylene-tetrahydrofolate. The non-reversible methylation of dUMP to dTMP results 
in the oxidation of N5-N10-methylene-THF to the inactive dihydrofolate, which can be converted 
back to THF by DHFR [31].  
For de novo methionine biosynthesis and methylation reactions, methylene 
tetrahydrofolate reductase (MTHFR) converts N5-N10-methylene-THF to 5-methyl-THF. This 
step creates the only source of 5-methyl-THF in the one carbon pathway. Methionine synthase 
(MTR or MS), a cobalamin dependent enzyme which is activated by methionine synthase 
reductase (MTRR or MSR), transfers one methyl group from 5-methyl-THF in order to convert 
homocysteine (Hcy) into methionine.  Dimethyl glycine is also produced from choline and 
betaine for methionine generation. Methionine synthesis ensures the provision of the universal 
methyl donor S-adenosyl methionine (SAM), with the activation of methionine by methionine 
adenosyl transferase and ATP. SAM is used to methylate more than 80 important biomolecules 
such as DNA, RNA, and proteins including histones. During this process, SAM is converted into 
S-adenosyl-homocysteine (SAH), which is either hydrolyzed to homocysteine (Hcy) to initiate a 
new remethylation cycle or transsulphurated to cysteine by cystathionine β-synthase [30]. 
In a cell, every methylation process requires a methyl group transfer from SAM. All of 
the metabolic methylation reactions are under the effect of SAM, which directs the utilization of 
Hcy and indicates the level of methylation. As explained before, the SAM/SAH ratio in a cell 
determines the cellular methylation potential. SAH is known to be an inhibitor of 
methyltransferases [23]. The level of SAM in the cell is regulated by two mechanisms. First of 
all, SAM suppresses the synthesis of N5-methylene-THF by inhibiting the MTHFR enzyme. 
Thus, methionine level and therefore Hcy level decreases when SAM increases. On the other 
hand, homocysteine can also be converted to methionine through SAH hydrolase. Therefore, N5-
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methylene-THF is an important molecule determining the pathway between remethylation and 
transsulphuration reactions. If there is sufficient N5-methylene-THF entering the methylation 
pathway, the direction of the SAH favors cysteine synthesis; if not, SAH is used to produce 
methionine [32]. The source of N5-methylene-THF is folate acquired by diet. Folate, as well as 
B12 and B6 vitamins, which function as co-enzymes for MTR and cysthation synthase, 
respectively, regulate the homocysteine removal and in turn, prevent SAH accumulation [33].  
 
1.6 Folate deficiency and DNA damage 
There is accumulating evidence that folate deficiency, either due to low dietary folate 
intake or due to low blood folate levels, is related to tumorigenesis [1]. Perturbations of the one 
carbon metabolism are thus, thought to play vital roles in neoplastic development by affecting 
gene regulation through DNA methylation and genome integrity through DNA synthesis and 
repair [34].Folate deficiency has been shown to induce hepatocellular carcinoma development in 
rats [1]. Diets deficient in various methyl donor groups (folic acid, choline, methionine and 
vitamin B12) have been shown to induce DNA hypomethylation, site-specific DNA 
hypermethylation, double strand breaks, and upregulation of DNMT’s [1]. 
Low dietary folate intake is strongly associated with DNA damage through uracil 
misincorporation or by DNA hypomethylation leading to genome instability [35]. Decreased 
cytosolic levels of N5-N10-methylene-THF caused by low folate status decreases the dTMP 
synthesis and increase the dUMP/dTMP ratio [35]. The increase of uracil pool in the cell elevates 
the rate of DNA-polymerase-mediated dUTP misincorporation into the DNA [36]. Uracil is 
excised from DNA by uracil-DNA glycosylase and apyrimidinic endonuclease, generating nicks 
which will be ligated by DNA ligase. However, if these nicks (single strand breaks) are located 
on two opposite strands, less repairable and hazardous double strand breaks may form. Uracil 
mediated double strand breakage is the major cause of deletions, duplications, chromosome 
breaks, micronucleus formation, chromatid recombinations, fragile sites and translocations which 
play important roles in tumorigenesis [35]. In cell culture, folate depletion can increase the 
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intracellular dUMP/dTMP ratio up to 10 fold. Folate depletion induced DNA breakage has been 
observed in lymphocytes and rodent cell lines in vitro [37], [38]. 
Decreasing folate levels can cause upregulation of DNA damage and cell cycle 
checkpoint related genes such as p53, p16 and p21 as well [37]. The normal levels of dNTPs for 
normal DNA/RNA synthesis are directly dependent on intracellular folate availability. 
Maintenance of folate concentration from diet or supplements is correlated with a protective 
effect and reduced incidence of number of cancers [39].  
On the other hand, genomic instability caused by global hypomethylation is characterized 
by an elevated rate of DNA sequence changes, aneuploidy, chromosome translocations and gene 
amplifications [40]. A balance between the two critical reactions (methylation and DNA 
synthesis/repair) must be reached so one does not compromise the other [41]. 
 
1.7 One carbon pathway enzyme variants 
Table 1 summarizes studies where polymorphic variants of the one carbon pathway 
enzyme activities were investigated utilizing various assays. From the enzymatic activity data 
obtained from the literature, one can infer that the variations of the enzymes partaking in SAM 
generation can create disturbances in the methylation process.  
 
 
1.7.1 Methylenetetrahydrofolate reductase (MTHFR) 
All four enzymes which I focused on in this study have allelic variants in the population 
and are associated with cancer. Different studies have focused on each of these alleles 
individually, despite the possibility that the net cumulative effect of various alleles is what 
ultimately determines SAM production efficiency. A large number of allelic variants of the one 
carbon pathway enzymes described. For example, there are 65 SNPs found on the MTHFR. 
However, among these, only 10 are gene non-synonymous SNPs that are found in more than 
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10% of the population are only 2 for MTHFR [42]. For some of these alleles, an association with 
decreased enzymatic activity has been described [42], (Table 1). Cancer risk generally has been 
linked to such hypomorphic alleles of one carbon pathway enzymes [33]. The major variant of 
the MTHFR gene, C677T transition (rs1801133), resulting in an Ala to Val change in aa.222, 
was found to decrease the activity of the MTHFR enzyme by %70 [43], (Table 1). This common 
variant of the MTHFR gene is associated with an increased risk of cancer [44]. MTHFR 677 TT 
homozygosity causes a significant increase in the homocysteine levels and DNA 
hypomethylation when compared to the wild-type allele [45]. 
Apart from the C677T transition, A1298C transition (rs1801131), converting Glu 429 to 
Ala, of the MTHFR enzyme causes a 15% reduction in the activity and results in increased levels 
of plasma homocysteine levels [45], Table 1. The impaired activity of MTHFR, especially along 
with the low folate status, results in less production of N5-methylene-THF and methionine, thus 
proceeds to hypomethylation [45]. In another study, carriers of A1298C polymorphism do not 
appear to have high levels of plasma Hcy (Table 1) but have a lesser degree of MTHFR activity 
reduction compared to C677T variants, when tested by biochemical assays [46]. However, when 
combined with other variants, A1298C polymorphism becomes effective in determining the Hcy 
and folate levels. Individuals heterozygote for both alleles for both the C677T and A1298C 
variants have significantly increased plasma Hcy levels when compared to 677 CC / 1298 AA 
homozygotes [47]. Although in several studies, the 677TT variant of MTHFR was found 
preferentially associated with cancer [48], in other studies, this variant was found to reduce 
cancer risk by directing the pathway to thymidine synthesis and thus preventing uracil 
accumulation [49]. In the MTHFR gene, as high as 65 SNP’s exist in a population of 240 
individuals. Interestingly, the combinations of different polymorphisms in the gene coding 
MTHFR result in an additive effect of reduction in the enzyme activity [42].  So, it becomes an 
important aspect to study the polymorphisms collectively to overcome the possibility of missing 
the effect of a polymorphism that can be observed only when within the context of a particular 
genotype.  
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1.7.2 Methionine synthase reductase (MTRR) 
Methionine synthase reductase (MTRR), an intermediate methyl carrier during the 
remethylation of Hcy to methionine, may be another important determinant of SAM production. 
In the past decade, an A to G polymorphism (A66G) in the 66th base pair (rs1801394), resulting 
in an isoleucine to methionine substitution in the 22nd aminoacid, was found to be associated 
with neural tube defects and cancer, especially in the absence of B12 vitamin and in the presence 
of the MTHFR C677T variant [48],[50]. In one study where a biochemical assay was used, 
demonstrated that the 66 GG variant of the MTRR enzyme had only 25% enzymatic activity 
compared to the wild-type protein [51], (Table 1). This low enzymatic activity results in an 
inefficient production of SAM [52]. This is likely due to the decreased capacity of MTRR to 
activate MTR, in turn would lead to impaired production of methionine from Hcy. Not 
independently, but when combined with the 677T MTHFR variant, a cell carrying the MTRR 
66G variant will have a lower capacity of remethylation, which will direct to DNA 
hypomethylation, instability and damage [48]. 
 
 
1.7.3 Methionine synthase (MTR) 
A variation in the methionine synthase (MTR) enzyme (A2756G), which results in a 
subsitution of aspartic acid to glycine in the 919th aminoacid, also decreases the rate of 
methylation of Hcy to methionine (rs1805087). Although an increased plasma Hcy concentration 
is not observed in neural tube defect patients carrying the hypomorphic allele, it is thought to 
have an additive effect along with other variants of other enzymes, and especially the MTRR 
variants [53]. This aspartic acid to glycine substitution occurs in the vicinity of the binding 
domain of vitamin B12 of the MTR [54]. It was observed that plasma homocysteine levels are 
lower in MTR 2756 GG individuals when compared to the more common AA genotype [48], 
(Table 1). 
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1.7.4 Reduced Folate Carrier (RFC) 
Another important variant in the one carbon pathway is in the reduced folate carrier 
(RFC) enzyme. The RFC gene codes an integral membrane protein which intakes the folate into 
the cell. A guanine to adenine transition (rs1051266) at the 80th base pair (G80A) of RFC is 
related to a moderate degree of elevated plasma Hcy and plasma folate levels [55]. This arginine 
to histidine transition results in a higher affinity of RFC for folate impairing its subsequent 
intracellular release [55]. A recent study pointed out that this polymorphism reduces N5-methyl-
tetrahydrofolate transport efficiency to 54% compared to the wild-type allele [56], (Table 1). 
1.7.5 Thymidylate synthase (TYMS) 
The enhancer region of the thymidylate synthase gene contains a number of 28-base-pair 
tandem repeats. These repeats are either two repeats or three repeats, while three repeats 
occurring most frequently. The triple repeat has been associated with a 2.6 fold increase in the 
expression of TYMS [57]. One study showed that 3rpt/3rpt subjects have lower plasma folate 
and higher plasma Hcy levels than those with other genotypes [58]. This tandem repeat 
polymorphism, combined with reduced folate intake, has been associated with lung 
adenocarcinomas, [59]. Conversely, among those individuals with the 3rpt/3rpt genotype, higher 
folate intake was correlated with a 50% reduced risk of cancer [60].On the other hand, in 
individuals carrying a 2rpt/2rpt genotype, higher folate intake is correlated with a 50% increased 
cancer risk [60].Similar results were shown for vitamin B12, but not with vitamin B6, methionine 
or alcohol intake [60]. 
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Table 1.The one-carbon pathway enzyme allele activity differences*. 
Enzymatic activity Assay Genotypes Reference 
  CC CT TT  
MTHFR C677T Micobiological 100% 65% 30% [53] 
 
Biochemical 100%  55% [42] 
 
RBC folate 100% 90% 82% [61] 
 
RBC folate 100% 90% 112% [45] 
 
Plasma folate 100% 96% 75% [45] 
 
Total Hcy 100% 101% 121% [55] 
 
Total Hcy 100% 108% 123% [45] 
 
DNA hypomethylation 100% 98% 121% [45] 
 
CpG Hypermethylation 100% 82% 28% [62] 
MTHFR A1298C      
 
 AA AC CC  
 
Biochemical 100%  102% [42] 
 
Plasma folate 100% 112% 114% [46] 
 
Plasma folate 100% 110% 107% [45] 
 
Total Hcy 100% 75% 77% [46] 
 
Total Hcy 100% 90% 115% [45] 
 
Genomic DNA methylation 100% 231% 182% [46] 
 
DNA hypomethylation 100% 102% 119% [45] 
 
CpG Hypermethylation 100% 107% 24% [62] 
 
 
    
MTR A2756G      
 
 AA AG GG  
 
CpG Hypermethylation 100% 28% 3% [62] 
 
 
    
 
 AA AG GG  
MTRR A66G Biochemical 100%  25% [51] 
 
 
    
 
 
    
 
 GG GA AA  
RFC G80A Plasma (total) Hcy 100% 103% 124% [55] 
 
5-CHO-mH4F transport 100%  57% [56] 
 
 
    
 
*Bold numbers show differences that were found to be statistically significant 
1.8 Cancer and one carbon pathway enzyme variants 
Epidemiologic studies where these alleles were studied individually and in pairs, 
suggested that they could be associated with cancer. Additive and synergistic effects of one 
carbon pathway enzyme variants and related dietary factors, such as folic acid and methionine 
 29 
 
consumption, are complex and in order to clarify the association of each allelic variant with 
cancer, these, as well as their interactions with dietary factors need to be studies carefully. On the 
basis of functional effects of these polymorphic variants, there ought to be a correlation between 
the incidence of cancer and the hypoactive alleles of these enzymes.  
However, there seems to be an inverse association between the MTHFR 677TT and 
cancer, especially in situations with sufficient folate intake [49]. A study has shown that the 
2rpt/2rpt phenotype of TYMS and MTHFR 677 TT together result in a statistically decreased 
risk of hepatocellular carcinoma [41], MTHFR 677TT and 1298CC, together, are also associated 
with a reduced risk of cancer [41].  It seems likely that in folate deficiency, MTHFR 677TT 
becomes almost totally incapable of producing N5-methylene-THF and thus, these cells have an 
impaired methylation capacity [52]. On the other hand, even when there is sufficient folate in the 
one carbon pool, the hypomorphic MTHFR protein will not be able to convert N5-N10-
methylene-THF effectively; so, TYMS will use it for thymidine synthesis. One can envision that 
because this will prevent the accumulation of uracil and therefore, prevent uracil 
misincorporation, the “T” allele will protect against tumorigenesis by avoiding DNA damage 
caused by dUMP. In contrast, the TT allele was also shown to increase the cancer risk by 2.64 
fold in folate deficiency and 1.6 fold in folate sufficiency [44]. Friso et al have shown that the 
MTHFR 677 TT allele associates with a significantly lower level of methyl cytosine in DNA, 
when compared to 677 CC and CT tissues, but only under conditions of low folate status [63]. At 
higher folate levels, the methyl cytosine levels did not differ from that among the 677 “CC” 
individuals [63]. That the 677 TT individuals have low levels of methyl cytosine in their DNA 
and elevated levels of plasma Hcy suggests that the MTHFR TT allele results in insufficient 
amounts of N5-methylene-THF that can’t meet the demands for the de novo methylation. In 
another study, the MTHFR 677TT and the MTRR 66GG variant combination showed the highest 
amount of DNA damage, calculated by micronucleus formation [47]. Vaughn et al showed that 
the MTRR alleles have no effect on plasma folate and plasma vitamin B12, in the presence of a 
677 CC or CT allele. However, in those individuals homozygous for the 677 T allele, the 
existence of MTRR AG or GG allele resulted in a significant increase in plasma homocysteine 
 30 
 
levels [64]. This observation suggests that the functional MTRR 66 A/A allele compensates for a 
hypoactive MTHFR 677 TT allele.  
It is worthwhile to point out that the association of MTHFR 677 variants is different in 
different stages and types of cancer. While the 677 CC and CT alleles are related to a reduced 
risk in renal cell carcionoma [65], they are related to an elevated risk in colorectal cancer [48]]. 
The effect may be different at different stages of the oncogenesis process. Supporting this is the 
observation that folate deficiency predisposes to colon cancer, but once neoplastic lesions are 
present, folate supplementation actually accelerates colon cancer transformation {Kim, 2003}. 
Folate supplementation after a certain stage of tumorigenesis may enhance DNA synthesis in an 
already transformed cell.  
In a study implemented by Chango et al, the RFC allele does not seem to affect plasma 
homocysteine levels when the MTHFR 677 allele is CC or CT. However, in the presence of the 
677 TT allele, RFC GA and AA will influence the utilization of folate [55].  
It is a challenging task to determine whether uracil misincorporation or errors in 
methylation process causes oncogenesis. Moreover, how the genes in the one carbon metabolism 
respond to folate deficiency is largely unknown. For instance, in the HCT116 cell line, folate 
deficiency appeared to preferentially shuttle the flow of one carbon units to the methionine cycle 
to protect methylation reactions and thereby suppress DNA synthesis. However in Caco2 cells in 
the same experimental setup, the metabolic priority in response to folate depletion was to shuttle 
the available folate pools to the nucleotide biosynthesis pathway at the expense of the methionine 
cycle [31].  
The studies of the one carbon pathway enzyme variants suggest that folate has an 
important role in modulating epigenetic features of the DNA that controls gene expression [66]. 
Since the end product of the one carbon pathway, S-adenosylmethionine, will be utilized for the 
de novo methylation of DNA, the efficiency of the production of SAM will affect gene 
expression via DNA methylation. Folate depletion is thought to cause tumorigenesis either by 
impairing methylation or by hindering DNA synthesis {Kim, 2003}. When the effects of one the 
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carbon metabolism enzymes are combined with the effects of low folate intake, significant 
results on the alterations of DNA methylation are obtained suggesting the roles of both events. 
.  
1.9 The aim of the study 
The role of DNA methylation in differentiation, disease and tissue specific gene 
expression has received considerable attention. In many circumstances, DNA methylation can on 
its own be an effective mechanism for gene silencing [24]. Methylated silent genes can be re-
activated by using demethylating agents [67]. It has been proposed that the methylation of CpG 
sites at gene promoter regions inhibits the recruitment of the transcription machinery and thus 
strongly represses the expression [24]. DNA methylation is proposed to be the basic mechanism 
for the regulation of CT genes such as MAGE [24] and SSX (Gure, 2005}. Interestingly, 
spermatogonia cells undergo epigenetic reprogramming, which involves genomic 
hypomethylation [68].  
Since genomic hypomethylation causes an increase in CT expression which is associated 
with developed stages of cancer and poor outcome (Gure, 2005}, the reversal of the genomic 
hypomethylation might improve prognosis. Because the methylation process requires the 
effective production of SAM by the one carbon pathway, we decided to investigate the 
relationship between CT gene expression and the allelic variants of the one carbon pathway, 
which we think are the primary effectors of SAM production.  
It is already known that a variety of enzyme variants in the one carbon pathway cause 
perturbations in the methylation cycle. Several epidemiologic studies have shown that variants of 
one carbon pathway enzymes are correlated with oncogenesis in different ways [69]. One can 
envision that the perturbations of the one carbon pathway hindering the methylation capacity of 
the cell may result in an additive effect resulting in DNA hypomethylation and might lead thus, 
to CT positivity and poor prognosis. We hypothesized that there could be a correlation between 
the allelic variants of the one carbon pathway enzymes and CT expression. The importance of 
such correlation would be that if CT positivity can be predicted by the allele variants a cancer 
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patient, the possible conversion of high CT expression to a low state by the addition of dietary 
supplements such as folic acid could improve the prognosis of the patient. 
One can envision that typing for the one carbon enzyme alleles among individuals who 
have a high-risk of developing cancer might help us suggest precautions towards restoring the 
patient’s impaired methylation capacity, such as the fortification or the supplementation of the 
diet by folic acid. 
In this study, I determined the one carbon pathway enzyme genotypes of lung cancer 
tumors and cell lines, and studied the correlation of these genotypes with CT expression levels. 
The allelic variants I chose to study were the non-synonymous, highly prevalent and for which 
there were a large number of epidemiologic studies indicating a correlation with cancer. The 
selected variants include MTHFR C677T, MTHFR A1298C, MTRR A66G, MTR A2756G and 
RFC G80A single nucleotide polymorphisms.  
I, thus, determined the one carbon enzyme genotypes of individuals who were previously 
typed for CT expression, using the restriction fragment length polymorphism assay (RFLP). In 
this method, the region containing the single nucleotide polymorphism (SNP) is amplified by 
PCR. The PCR product is subsequently digested with a specific endonuclease, which can 
recognize and cut DNA wherever a specific short sequence exists. This process is called a 
restriction digestion. This method can only be used if the allelic variant can be distinguished by a 
specific restriction endonuclease. Thus, restriction enzymes were selected such that the PCR 
product of one allele would be digested whereas the other allele would not. When the digestion 
products are analyzed by agarose gel electrophoresis, the allele is determined according to the 
molecular weights of the digestion products.  
In summary, apart from many epigenetic mechanisms which may be perturbed in cancer, 
DNA hypomethylation seem to be the major actor for the ectopic expression of CT genes. By 
elucidating the underlying mechanisms which might thus cause CT expression, we potentially 
will have described a novel biomarker useful for the determination of tumorigenesis as well as 
improving the prognosis and lifespan of a cancer patient.  
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CHAPTER 2. MATERIALS AND METHODS 
2.1 The PCR Method 
The standart reaction mixture contained 1µg of genomic DNA, 1µl of 10mM dNTP mix 
(Finnzymes, Cat. No: F-506L), 2µl of 25mM primer mix, 2.5 µl of 10X Buffer (Finnzymes 
Dnazyme II HotStart Reaction Buffer, Cat. No: F-522), 0.5 µl Hot Start Taq Polymerase 
(Finnzymes, Cat. No: F-504L) added up to 25 µl with ddH2O. Then, the tubes are transferred to 
the Perkin Elmer (PE9700) thermal cycler for 35 cycles. Before the reaction, initial denaturation 
was performed at 94 oC for 10mins. Each cycle consisted of 30sec at 94 oC, 30sec at Tm oC, and 
30 sec at 72 oC. Then, the mixture was incubated at 72 oC for 7mins for final annealing and a 
final hold of 4 oC. See Table 2 for primer pairs, Tm values and Table 3 for nested primers. 
Table 2. PCR primers used for RFLP analysis 
Gene Name and SNP Gene ID Ref. Seq. Primers  Tm Product Size(bp) 
MTHFR C677T 4524 AY338232.1 5’ – TTTGAGGCTGACCTGAAGCAC – 3’ (sense) IIF 
3’ – GACCTGAGAGGAGATCTGG – 5'  (antisense) IIR 
60C 288 (8,700nt-8,988nt) 
MTHFR A1298C 4524 AY338232.1 5’ – GAGGAGCTGCTGAAGATGTG -3’ (sense) IIF 
3’- TGGAGGTCTCCCAACTTACC -5’(antisense) IIR 
 65C 261 (10,605nt-10,866nt) 
MTR A2756G 4548 NT_004836 5’- TGTTATCAGCATTGACCATTACTACAC -3’(sense) IIF 
3’- ACTGTTTCAGCACCTGTTTCCC -5’ (antisense) IIR 
 
 
65C 498 (105,261nt-105,759nt) 
MTRR G66A 4552 NT_006576 5’ - GCAAAGGCCATCGCAGAAGACAT -3’(sense) IF 
3’- CACTTGTTCTCACAGCCACCC -5’(antisense) IIR 
 
 
60C 380 (7,860,967nt-7,861,347nt) 
RFC G80A 6573 AL163302.2 5’ – CTCCCGCGTGAAGTTCTT -3’ (sense) IF  
3’ – AGCGTCACCTTCGTCCCCTC -5’ (antisense) IIR 
 
 
60C 231 ( 236,569nt-236,800nt) 
TS Polymorphism 7298 NC_000018.8 5' - GTTCCCGGGTTTCCTAAGAC -3' (sense) IIF 
3'- GATCTGCCCCAGGTACTGCA -5' (antisense) IIR 
 
 
65C 390 
TS Expression 7298 NC_000018.8 5' - GCAGATCCAACACATCCTCC - 3' (sense)  
3' - CCATTGGCATCCCAGATTTTCAC -5' (antisense) 
 
60C 236 
 
 
 34 
 
Table 3. Nested PCR primers used for RFLP analysis 
Gene Name and 
SNP 
Ref. Seq. Nested Primers Product size (bp) 
nested 
Tm 
     
MTHFR C677T AY338232.1 5’- TGAAGGAGAAGGTGTCTGCGGGA – 3’ (sense nested) IF 
3’- AGGACGGTGCGGTGAGAGTG -5’ (antisense nested) IR 
198 (8723nt-8921nt) 60oC 
    
MTHFR A1298C AY338232.1 5’ – GAGGAGCTGACCAGTGAAG -3’(sense nested) IF 
3’- GGTAAGTTGGGAGACCTCCA -5’ (antisense nested) IR 
136 (10.629nt-10.765nt) 60oC 
    
MTR A2756G NT_004836 5’- TGTTCCCAGCTGTTAGATGAAAATC -3’(sense nested) IF 
3’- GATCCAAAGCCTTTTACACTCCTC – 5’(antisense nested) IR 
211(105.334nt-
105.545nt) 
65oC 
    
MTRR G66A NT_006576 3’-GTGAAGATCTGCAGAAAATCCATGTA -5’(antisense nested) IR* 66bp (7,860,967nt-
7,861,032nt) 
60oC 
     
RFC G80A AL163302.2 5’- AGCCGTAGAAGCAAAGGTAGC – 3’(sense nested) IIF 
3’ – TGCATTCGTCTCCAGGGTG – 5’(antisense nested) IR 
154bp (236,646nt-
236,667nt) 
55oC 
    
TS NC_000018.8 5'-AGCAGGAAGAGGCGGAGC-3'(sense nested) 
3'- CCGGCCACAGGCATG -5'(antisense nested) 
172bp 60oC 
    
*The 5’(forward) nested primer used for MTRR was identical to that shown in Table 2.  
 
 
 
2.2 DNA Samples 
Tumor samples from 763 lung cancer patients were previously collected and typed for 
CT expression (Gure, 2005). All of the samples were scored for the positivity of CT expression. 
The scores corresponding to different expression levels of each CT gene ranged between a 
negative (-) to three positives (+++). We then selected, genomic DNA prepared from these tumor 
samples with the highest and the lowest amount of CT expression and used them for one carbon 
pathway allele genotype analysis. Table 4 shows the label, cancer type and the CT expression 
scores of the samples. Table 4a and Table 4b the CT(+) and CT (-) lung cancer samples used to 
for this study respectively. 
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Table 4. CT gene expression profile of CT (+) tumor samples 
Lu CT(+) HISTOLOGY NY-ESO-1 LAGE-1 MAGE-A1 MAGE-A3 MAGE-A4 MAGE-A10 CT-7 SSX-2 SSX-4 
31 SQCC (+++) (+/-) (+) (+++) (+++)   (+)     
68 Adeno (+++)   (+) (+)     (-)     
87 Adeno (-) (-) (+++) (+++)     (+++)     
89 Adeno (+++) (+++) (+++) (+++) (+/-) (+) (+/-)     
111 Lgcell (-) (-) (+++) (+++) (+++)   (+++)     
131 SQCC (+++) (+/-) (+) (+++) (+++)         
168 SQCC (+++) (+++) (+++) (+++) (+++)   (+)     
185 NSCLC (+++) (+++) (+++) (+++) (+/-) (-) (-) (++) (-) 
186 Adeno (+++) (+++)   (+++)           
219 SQCC (+) (+) (+++) (+++) (+++)   (-) (+/-) (+++) 
223 SQCC (+++) (+++)   (+++) (-)         
649 AdenoBAC (+++) (+/-) (+++) (+++) (+/-) (+++) (-) (-)   
652 SQCC (+++) (+++) (+++) (+++) (+++) (+++) (-) (-)   
658 AdenoBAC (+/-) (+++) (+++) (+++) (+++) (+/-)   (+++)   
726 Adeno (+++) (+++) (+++) (+++) (+++) (+++)   (++) (+++) 
736 Adeno (+++) (+++) (+++) (+++) (+++) (+++)   (+/-) (-) 
739 Lgcell (+++) (+++) (+++) (+++) (+++) (+++)   (++) (+++) 
745 SQCC (+++) (+++) (+++) (+++) (+++) (+/-)   (++) (-) 
752   (+++) (+++) (+++) (+++) (+++) (+/-)   (-) (-) 
753   (++) (+/-) (+++) (+++) (+++) (+/-)     (-) 
759   (+++) (+++) (+++) (+++) (+++) (+/-)     (-) 
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Table 5. CT gene expression profile of CT(-) tumor samples 
Lu CT(-) HISTOLOGY NY-ESO-1 LAGE-1 MAGE-A1 MAGE-A3 MAGE-A4 MAGE-A10 CT-7 SSX-2 SSX-4 
69 BAC (-) (-) (-) (-)     (-)     
77 SQCC (-) (-) (-) (-)     (-)     
88 Adeno (-) (-) (-) (-)     (-)     
90 Adeno (-) (-) (-) (-)     (-)     
108 Adeno (-) (-) (-) (-)     (-)     
110 Adeno (-) (-) (-) (-)     (-)     
112 SQCC (-) (-) (-) (-)     (-)     
180 Adeno (-) (-) (-) (-)     (-) (-) (-) 
183 BAC (-) (-) (-) (-)     (-) (-) (-) 
191 Adeno (-) (-) (-) (-) (-)   (-)     
221 Adeno (-) (-) (-)   (-)   (-)     
225 Adeno (-) (-) (-) (-) (-)   (-) (-) (-) 
639 AdenoBAC (-) (-) (-) (-) (-) (-) (-)     
656 AdenoBAC (-) (-) (-) (-) (-) (-)       
657 SQCC (-) (-) (-) (-) (-) (-)       
670 AdenoBAC (-) (-) (-) (-) (-) (-)       
692 AdenoBAC (-) (-) (-) (-) (-) (-)   (-) (-) 
693   (-) (-) (-) (-) (-) (-)   (-) (-) 
694   (-) (-) (-) (-) (-) (-)   (-) (-) 
698 Adeno (-) (-) (-) (-) (-) (-)   (-) (-) 
706 Adeno (-) (-) (-) (-) (-) (-)   (-) (-) 
707 Adeno (-) (-) (-) (-) (-) (-)   (-) (-) 
713 AdenoBAC (-) (-) (-) (-) (-) (-)   (-) (-) 
716 Adeno (-) (-) (-) (-) (-) (-)   (-) (-) 
718 AdenoBAC (-) (-) (-) (-) (-) (-)   (-) (-) 
728 AdenoBAC (-) (-) (-) (-) (-) (-)   (-) (-) 
748 AdenoBAC (-) (-) (-) (-) (-) (-)   (-) (-) 
749 Adeno (-) (-) (-) (-) (-) (-)   (-) (-) 
751 AdenoBAC (-) (-) (-) (-) (-) (-)   (-) (-) 
763   (-) (-) (-) (-) (-) (-)       
 
 
 
2.3 Restriction Fragment Length Polymorphism (RFLP) Analysis  
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RFLP analysis was done as previously described [43]. Following the PCR reaction, 5 µl 
of PCR product was mixed with 1 µl of restriction endonuclease enzyme (New England 
Biolabs), 1 µl of Buffer 2 (New England Biolabs), added up to 10 µl with ddH2O. The mixture 
was incubated at 37oC overnight. Table 4 shows the expected sizes of the digestion products for 
each primer pair.  
Table 6. Expected RFLP product sizes 
Polymorphism and 
Restriction endonuclease 
Primers 
IIF-IIR  IIF-IR IF-IIR IF-IR 
MTHFR C677T C/C (HinF1I) 288 220 266 198 
MTHFR C677T C/T (HinF1I) 288, 241, 47 220, 173, 47 266, 241, 25 198, 173, 25 
MTHFR C677T T/T (HinF1I) 241, 47 173, 47 241, 25 173, 25 
     
MTHFR A1298C C/C (MboII) 266 160 237 136 
MTHFR A1298C C/A (MboII) 261, 209, 28, 24 160, 108, 28, 24 237, 209, 28 136, 108, 28 
MTHFR A1298C A/A(MboII) 209, 28, 24 208, 28, 24 209, 28 108, 28 
     
MTR A2756G A/A (HaeIII) 498 284 425 211 
MTR A2756G A/G (HaeIII) 498, 345, 153 284, 153, 131 425, 345, 80 211, 131, 80 
MTR A2756G G/G (HaeIII) 345, 153 153, 131 345, 80 131, 80 
     
MTRR G66A G/G (Nde1) - - 381 66 
MTRR G66A G/A (Nde1) - - 381, 317, 39, 25 66, 42, 24 
MTRR G66A A/A (Nde1) - - 317, 39, 25 42, 24 
     
RFC G80A A/A (HinP1I) 287 154 364 231 
RFC G80A A/G (HinP1I) 287, 257, 30 154, 124, 30 364, 257, 70, 37 231, 124, 70,37 
RFC G80A G/G (HinP1I) 257, 30 124, 30 257, 70, 37 124, 70, 37 
 
 
2.3.1 Digestion Products 
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 2.3.1.1 MTHFR C677T 
 The MTHFR C677T polymorphism creates a HinF1I restriction site. Table 6 shows the 
transition of the protein and the nucleotide sequence and the digestion products of all alleles. 
Upon digestion, HinF1I will be able to cut the “T” allele whereas the “C” allele will remain 
uncut. 
Table 7. A222V (C677T) variant of the MTHFR gene 
 
• Amino acid sequence A222V (Ref Seq: NM_005957): 
 
 
  151- KNIMALRGDP IGDQWEEEEG GFNYAVDLVK HIRSEFGDYF DICVAGYPKG 
  201- HPEAGSFEAD LKHLKEKVSA GADFIITQLF FEADTFFRFV KACTDMGITC 
  251- PIVPGIFPIQ GYHSLRQLVK LSKLEVPQEI KDVIEPIKDN DAAIRNYGIE 
 
• Nucleotide Sequence C677T (Ref Seq:  NM_005957):  
GANTC – HinF1I restriction site 
      781 aggccacccc gaagcaggga gctttgaggc tgacctgaag cacttgaagg agaaggtgtc 
      841 tgcgggagcc gatttcatca tcacgcagct tttctttgag gctgacacat tcttccgctt 
      901 tgtgaaggca tgcaccgaca tgggcatcac ttgccccatc gtccccggga tctttcccat 
      961 ccagggctac cactcccttc ggcagcttgt gaagctgtcc aagctggagg tgccacagga 
     1021 gatcaaggac gtgattgagc caatcaaaga caacgatgct gccatccgca actatggca 
 
 
           C/T          T/T           C/C 
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2.3.1.2 MTHFR A1298C 
 Upon the transition of adenine to cytosine at the 1298th position of the MTHFR gene, the 
recognition site of the MboII enzyme becomes abolished. Therefore, the undigested products will 
indicate the presence of an “C” allele whereas the “A” allele will result in digestion. The amino 
acid and the nucleotide alterations are designated in Table 7.  
Table 8. E429A (A1298C) variant of the MTHFR gene  
 
Amino acid sequence E429A (Ref Seq: NM_005957): 
 
  351- LSAHPKRREE DVRPIFWASR PKSYIYRTQE WDEFPNGRWG NSSSPAFGEL 
  401- KDYYLFYLKS KSPKEELLKM WGEELTSEES VFEVFVLYLS GEPNRNGHKV 
  451- TCLPWNDEPL AAETSLLKEE LLRVNRQGIL TINSQPNING KPSSDPIVGW 
  
• Nucleotide Sequence A1298C (Ref Seq:  NM_005957):   
GAAGA…N8 –MboII restriction site 
     1321 ggagtgggac gagttcccta acggccgctg gggcaattcc tcttcccctg cctttgggga 
     1381 gctgaaggac tactacctct tctacctgaa gagcaagtcc cccaaggagg agctgctgaa 
     1441 gatgtggggg gaggagctga ccagtgaaga aagtgtcttt gaagtcttcg ttctttacct 
     1501 ctcgggagaa ccaaaccgga atggtcacaa agtgacttgc ctgccctgga acgatgagcc 
     1561 cctggcggct gagaccagcc tgctgaagga ggagctgctg cgggtgaacc gccagggcat 
     1621 cctcaccatc aactcacagc ccaacatcaa cgggaagccg tcctccgacc ccatcgtggg 
      
        C/C          A/C           A/A  
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2.3.1.3 MTR A2756G 
 The A to G transition of this polymorphism creates a HaeIII restriction site. Thus, the G 
allele will be able to be digested. The information about the transition is indicated in Table 8. 
  Table 9. D919G (A2756G) variant of the MTR gene 
 
• Amino acid sequence D919G (Ref Seq: NP_000245): 
 
      781 kgdvhdigkn ivgvvlgcnn frvidlgvmt pcdkilkaal dhkadiigls glitpsldem 
      841 ifvakemerl airiplligg attskthtav kiaprysapv ihvldasksv vvcsqllden 
      901 lkdeyfeeim eeyedirqdh yeslkerryl plsqarksgf qmdwlsephp vkptfigtqv 
      961 fedydlqklv dyidwkpffd vwqlrgkypn rgfpkifndk tvggearkvy ddahnmlntl 
 
 
• Nucleotide Sequence A2756G (Ref Seq: NC_000001):  
     GGCC – HaeIII restriction site 
    89641 attgaccatt actacaccag ttttatcatc ttttgctcat ctatggctat cttgcatttt 
    89701 cagtgttccc agctgttaga tgaaaatcta aaggatgaat actttgagga aatcatggaa 
    89761 gaatatgaag atattagaca ggaccattat gagtctctca aggtaagtgg tagaaacaga 
    89821 tttttgcttg tttttaatgt gactgttttt tatgatccta gtttttaatg tgacttttta 
    89881 aaatggtttt gaggagtgta aaaggctttg gatcatttta gagaatttct gtcttctagt 
 
 
 
 
 
 41 
 
2.3.1.4 MTRR A66G 
 The A66G transition in the MTRR gene, upon with a substitution of a base with modified 
primers, creates a restriction site for the NdeI enzyme. The “A” allele will produce digested 
products where as the “G” allele will remain uncut. 
   Table 10. I22M (A66G) variant of the MTRR gene 
 
 
• Amino acid sequence I22M (Ref Seq: NP_002445): 
  
        1 mrrflllyat qqgqakaiae eiceqavvhg fsadlhcise sdkydlktet aplvvvvstt 
       61 gtgdppdtar kfvkeiqnqt lpvdffahlr ygllglgdse ytyfcnggki idkrlqelga 
      121 rhfydtghad dcvglelvve pwiaglwpal rkhfrssrgq eeisgalpva spassrtdlv 
 
• Nucleotide Sequence A66G (Ref Seq: NC_000005):  
 CATATG – Nde1 restriction site           gcaaaggccatcgcagaagcaat -primer with a modified base 
 
 
     1681 gccttgaagt gatgaggagg tttctgttac tatatgctac acagcaggga caggcaaagg 
     1741 ccatcgcaga agaaatatgt gagcaagctg tggtacatgg attttctgca gatcttcact 
     1801 gtattagtga atccgataag gttagagccg ttacagtgga ttttaccgtt ttgtgctttg 
     1861 aagaattttg gttgggaagt gatatttatg aaacaaaagg acactaatac caccacatag 
     1921 tctttgtttt ttaacagaaa tgtgtttgtt caatggtata gtaagatatc accagcattt 
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2.3.1.5 RFC G80A 
 The G to A transition at the 80th base of the RFC gene abolishes a HinP1I restriction site. 
So, the G allele will be recognized and cut by HinP1I whereas the A allele will be undigested.  
 
Table 11. R27H (G80A) variant of the RFC gene 
 
 
 
• Amino acid sequence R27H (Ref Seq: NP_919231): 
 
        1 mvpsspavek qvpvepgpdp elrswrhlvc ylcfygfmaq irpgesfitp yllgpdknft 
       61 reqvtneitp vlsysylavl vpvflltdyl rytpvlllqg lsfvsvwlll llghsvahmq 
      121 lmelfysvtm aariayssyi fslvrparyq rvagysraav llgvftssvl gqllvtvgrv 
       
 
• Nucleotide Sequence G80A (Ref Seq: NC_000021):   
GCGC – HinP1I restriction site 
 
     4441 ccttcgtccc ctccggagct gcacgtggcc tgagcaggat ggtgccctcc agcccagcgg 
     4501 tggagaagca ggtgcccgtg gaacctgggc ctgaccccga gctccggtcc tggcggcacc 
     4561 tcgtgtgcta cctttgcttc tacggcttca tggcgcagat acggccaggg gagagcttca 
     4621 tcacccccta cctcctgggg cccgacaaga acttcacgcg ggagcaggca tgtgggtgcc 
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2.4 c-DNA Synthesis 
c-DNA synthesis was carried out with a c-DNA synthesis kit (Finnzymes DyNAmo 
cDNA synthesis kit, #F-470L). The master mix contained 10 µl of 2X RT Buffer, 1 µl of random 
hexamer primer set with a concentration of 300µg/µl, 2 µ l of M-MuLV Rnase H+ reverse 
transcriptase, maximum 1 µg of template RNA added up to 20 µl with ddH2O. After transferring 
to the Perkin Elmer (PE9700) thermal cycler, the mixture was incubated in the following 
conditions: 25 oC for 10 mins, 37 oC for 30mins, 85 oC for 5 mins and a final hold of 4 oC. 
 
2.5 Cell Culture  
Cells were grown at a confluence of approximately 80% in RPMI with 10% fetal calf 
serum (Hycole), supplemented with glutamine, streptomycin and penicillin. The old medium was 
removed and the cells were washed with 1X PBS. After removal of the 1X PBS, Trypsin/EDTA 
solution was added and the cells were left for incubation at 37C for 3 - 4 minutes. When the cells 
were detached from the surface of the plate, trypsin was inactivated by adding fresh growth 
medium. The detached cells were suspended using a pipettor and were placed in a falcon tube. 
The cells then were centrifuged at 800rpm for 5mins and the supernatant containing the 
Trypsin/EDTA solution was removed. The pellet was re-suspended with fresh medium and cell 
suspension was plated to a new flask. Fresh medium is added to the flask and placed in 37 oC, 
%5 CO2 incubator. 
 
2.6 RNA Isolation  
Cells were trypsinized as previously described in the Cell Culture section. Cold media is 
added and the cells are mixed. The cells are transferred into a 15ml falcon tube and centrifuged 
at 800rpm for 5 mins, at 4 oC. After centrifugation, the media was removed and washed with 1X 
PBS and 1ml Trizol (Invitrogen) was added. The cells were mixed until they homogenize and 
transferred into an eppendorf tube. 200µl chloroform was added and the tube was vigorously 
shaken for 15 seconds. After incubating for 3 minutes at room temperature, the cells were 
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centrifuged at 13.000rpm for 15 mins, at 4 oC. After this step, the supernatant was removed by a 
pipettor and placed into a new tube. 500 µl isopropanol was added and the supernatant is mixed. 
The mixture was incubated for 10 mins at room temperature and centrifuged at 13.000 rpm for 
10 minutes, at 4 oC.  Then the isopropanol was completely removed and 1ml 75% EtOH was 
added following 8 minutes of centriguation at 8000rpm, at 4 oC. The 75% EtOH wassucked and 
1ml 99.8% EtOH was added following the same centrifugation step of 8 mins at 8000rpm, 4 oC. 
99.8% EtOH was removed and the pellet is dried under laminar flow for 5-10mins. Lastly, the 
pellet is dissolved in 20µ l-25µl DNase-RNase free H2O and mixed 
 
2.7 Real Time PCR 
The real-time RT-PCR assays were done with the iCycler instrument (BioRad 
Laboratories) using the Finnzymes Dynamo SYBR Green qPCR kit (Finnzymes Cat #F-410). 
The primers used for TS expression were 5' -GCAGATCCAACACATCCTCC-3' (sense) and 3'- 
CCATTGGCATCCCAGATTTTCAC-5' (antisense). β-actin was used as a loading control. The 
PCR reactions were set up in a volume of 20 µl, containing 2 µl of sample cDNA, 10 µl  of  2X 
Master mix, 5 pmol from each TS specific primers, added up to 20 µl with RNase-DNase free 
water. The cycling conditions were as follows: 95 °C for 1 min, 58 °C for 1 min, and 72 °C for 
1min for 40 cycles with initial melting at 95 °C for 10 min. 
Relative expression levels were calculated using the PCR threshold cycle number (CT) 
for each sample and control sample (both of which were normalized according to β-actin mRNA 
for differences in amount of total RNA added to the reaction), using the formula 
2−(∆CTsample−∆CTcontrol) [70], [71]. ∆CT represents the difference in CT values between the target and 
β-actin transcripts. RT-PCR was performed in triplicates for each sample and average CT values 
were calculated 
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2.8 Statistical Analysis 
For the significance tests used in the percentage tables, chi-square test was used. The 
significance level was determined as p=0.05. For the sample number calculation tests, univariate 
logistic regression model analysis (Wald’s test) was performed by the Power and Precision 
software. Multivariate logistic regression models were done by applying an algorithm in R 
software [83]. For both of the tests the significance level was set to α=0.05. The event rate is 
defined as the probability of a genotype being CT (+). The power of the analysis is defined as the 
ability of the test to differentiate the difference between the alleles in terms of CT expression. 
The odds ratio in multivariate tests indicates the ratio of the probability of a genotype being a CT 
(+) sample divided by the probability of the same genotype being a CT (-) sample and the 
division of the probabilities of the other genotypes being CT (+) and CT (-) samples, 
respectively. An exemplary formula showing this ratio for the MTHFR 677 polymorphism is 
indicated below. The estimate values in the multivariate test is calculated as log(OR).     
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CHAPTER 3. RESULTS 
 
3.1 One carbon pathway enzyme genotype frequencies of lung cancer patients 
All 50 lung cancer samples were typed for five allelic variants, except for MTR A2756G 
and MTRR G66A, for which 1 and 4 samples could not be typed, respectively. We observed a 
frequency of 44 % CC, 34% CT and 11% TT for the MTHFR C677T polymorphism, 48% AA, 
46% AC and 6% CC for MTHFR A1298C, 52% AA and 48% AG for MTR A2756G, 38.1% 
AA, 47.6% AG and 14.3% GG for MTRR A66G and 22% GG, 56% AG and 22% GG genotypes 
for RFC G80A polymorphisms.. 
 Next, we checked to see whether our lung cancer sample panel was in Hardy-Weinberg 
equilibrium. For this reason, we calculated the expected frequencies of each genotype and 
evaluated chi-square analysis for observed/expected ratio. The genotype frequencies for all the 
polymorphisms were in accordance with the Hardy–Weinberg equilibrium: MTHFR C677T 
(p=0.4), MTHFR A1298C (p=0.7), MTR A2756G (p=0.08), MTRR A66G (p=1) and RFC G80A 
(p=0.9). Table 12 summarizes our observations and expected values for each genotype. 
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Table 12 One carbon enzyme distributions in lung cancer patients and Hardy-Weinberg expectations. 
Polymorphism Genotype Observed Observed/ 
Expected 
χ
2
 value p* 
      
MTHFR677 CC 21 1.1   
 CT 19 0.8   
 TT 10 1.3 2.0 0.4 
      
MTHFR1298 AA 24 1   
 AC 23 1.1   
 CC 3 0.7 0.7 0.7 
      
MTR2756 AA 25 0.9   
 AG 24 1.3   
 GG 0 - 5.2 0.08 
 Undetermined (1)     
      
MTRR66 GG 16 1   
 GA 20 1   
 AA 6 1 0.004 1 
 Undetermined (4)     
      
RFC80 GG 11 0.9   
 GA 27 1.1   
 AA 12 0.9 0.3 0.9 
       
       
*Chi square 
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3.2 Distribution of one carbon enzyme genotypes among CT (+) and CT (-) lung cancer 
patients I 
Among CT (+) samples the distribution was 44% CC, 26% CT and 30 % TT, while CT (-) 
samples’ distribution was 31% CC, 41% CT and 28% TT.  
The distribution of other polymorphisms was not significantly different when samples 
were stratified for CT gene expression. The MTHFR A1298C polymorphism, the distribution 
was 57% AA, 38% AC and 5% CC for CT (+) lung cancer samples and, 41% AA, 52% AC and 
7% CC among the CT (-) samples.  
The observed genotype frequencies for the MTR A2756G polymorphism were 63% AA 
and 37% AG among the CT (+); 55% AA and 45% AG among the CT (-) samples. For the 
MTRR A66G polymorphism, our observation for the CT (+) lung cancer samples was a 
frequency of 35% AA, 55% AG and 10% GG genotypes. On the other hand, CT (-) lung cancer 
samples were 35% AA, 46% AG and 19% GG. 
We found 29% GG, 48% AG and 24% AA genotype frequency in CT (+) samples for the 
RFC G80A polymorphism. Among the CT (-) samples, the distribution was 17% GG, 59% AG 
and 24% AA. 
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Table 13. Distribution of 1-carbon enzyme genotypes among CT-positive and -negative lung cancer patients I: 
Chi-square test. 
 
Polymorphism Genotype CT(+) CT(-) p* 
     
MTHFR677 CC 12 (44%) 9 (31%)  
 CT 7 (26%) 12 (41%)  
 TT 2 (30%) 8 (28%) 0.02 
     
MTHFR1298 AA 12 (57%) 12 (41%)  
 AC 8 (38%) 15 (52%)  
 CC 1 (5%) 2 (7%) 0.2 
     
MTR2756 AA 10 (63%) 16 (55%)  
 AG 11 (37%) 13 (45%)  
 GG 0 (0%) 0 (0%) 0.3 
     
MTRR66 GG 7 (35%) 9 (35%)  
 GA 11 (55%) 12 (46%)  
 AA 2 (10%) 5 (19%) 0.3 
 Undetermined 4   
     
RFC80 GG 6 (29%) 5 (17%)  
 GA 10 (48%) 17 (59%)  
 AA 5 (24%) 7 (24%) 0.2 
      
      
*Chi square 
 
Next, for each polymorphism, we grouped heterozygotes with the homozygote where 
both showed a similar bias towards a given CT expression phenotype, and thus generated 2 by 2 
charts. The odds ratio calculated from these charts demonstrated borderline significance for the 
MTHFR677 polymorphism, with an odds ratio of 2.96, when other polymorphisms, when thus 
evaluated, were not significantly different when CT(+) and (-) samples were compared (Table 
14). Both analyses suggest that the hypoactive MTHFR677 CT/TT phenotypes preferentially 
associate with lack of CT gene expression.  . 
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Table 14.Distribution of 1-carbon enzyme genotypes among CT (+) and CT (-) lung cancer patients II: Odds 
ratios  
Polymorphism Genotype CT(+) CT(-) OR (95% CI) p* 
      
MTHFR677 CC 12 9   
 CT/TT 9 20 2.96 (0.92-9.53) 0.07 
      
      
MTHFR1298 AA 12 12   
 AC/CC 9 17 1.89 (0.61-5.89) 0.3 
      
      
MTR2756 AA 10 16   
 AG/GG 11 13 0.85 (0.28-2.61) 0.6 
      
      
MTRR66 GG 7 9   
 GA/AA 13 17 0.9 (0.26-3.2) 0.8 
 Undetermined 4    
      
RFC80 GG 6 5   
 GA/AA 15 24 1.92 (0.5-7.41) 0.3 
      
*Fisher’s exact test (2-sided) 
 
 
3.3 One carbon enzyme allele distribution among CT-positive and -negative lung cancer 
patient. 
 Since the previous analyses suggested an association between the MTHFR677 CT and 
TT genotypes with the lack of CT gene expression, we tested whether a similar association could 
be found for a given allele. As shown in Table 15, the hypoactive T allele of the MTHFR677 
polymorphism was strongly associated with the lack of CT gene expression as well. We did not 
observe a significant association between CT gene expression and the presence of any other 
allele (Table 15). 
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Table 15. One carbon enzyme allele distribution among CT-positive and -negative lung cancer patients. 
 
Polymorphism Allele CT(+) CT(-) OR (95% CI) p* 
      
MTHFR677 C 31 11   
 T 30 28 2.63 (1.11-6.21) 0.025 
      
      
MTHFR1298 A 32 10   
 C 39 19 1.56 (0.64-3.82) 0.3 
      
      
MTR2756 A 31 11   
 G 45 13 0.81 (0.32-2.05) 0.7 
      
      
MTRR66 G 25 15   
 A 30 22 1.22 (0.53-2.84) 0.6 
      
      
RFC80 G 22 20   
 A 27 31 1.26 (0.57-2.8) 0.6 
      
*Fishers exact test (2-sided) 
 
 
 
3.4 CT expression associations with one carbon enzyme genotype combinations in lung cancer 
patients  
 Since combinations of genotypes are known to result in inefficient utilization of folate, as 
well as decreased enzymatic activity, we tested whether a given combination of two genotypes 
would result in a significant stratification of samples based on CT gene expression. Among all 
possible two-by-two combinations, we found borderline significance between the lack of CT 
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expression and the presence of both the MTHFR677 “CC or TT” genotype, and the RFC80 “GG 
or AA” genotype (Table 16); as well as when the MTHFR1298 “AC or CC” genotype was 
combined with the RFC80 “GG or AA” genotype (Table 17). This is in line with what we 
observed for individual genotype associations with CT gene expression, therefore, that 
hypomorphic genotypes in the 1-carbon pathway associate with the lack of CT gene expression 
in tumors.    
 
Table 16. CT expression associations with 1-carbon enzyme genotype combinations in lung cancer patients I: 
MTHFR677 C>T and RFC80 G>A. 
 
 
RFC80 
MTHFR677 CT(+) CT(-) OR (95% CI) p* 
      
GG CC  8 9 1.9 (0.51-7.05) 0.05 
GG  CT/TT 7 15   
      
GA/AA  CC  4 0 - 0.3 
GA/AA CT/TT 2 5   
      
*Fisher’s exact test (2-sided) 
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Table 17. CT expression associations with 1-carbon enzyme genotype combinations in lung cancer patients II: 
MTHFR1298 A>C and RFC80 G>A 
 
 
RFC80 
MTHFR1298 CT(+) CT(-) OR (95% CI) p* 
      
GG AA  2 4 0.13 (0.01-2) 0.2 
GG  AC/CC 4 1   
      
GA/AA  AA  10 8 4 (1.01-15.71) 0.06 
GA/AA AC/CC 5 16   
      
*Fishers exact test (2-sided) 
 
 
3.5 One carbon enzyme genotype associations in lung cancer patients 
 We tested whether the presence of genotype correlated with that of another. When all 
lung cancer samples were evaluated, we observed a significant negative correlation between the 
MTHFR677 CC and MTRR66 GG genotypes, between the MTHFR1298 AA and MTHFR66 
GG genotypes, and co-occurrence of RFC80 “GG or GA” genotype with MTHFR1298 AA, as 
well as with MTHFR677 CC (Table 18). A positive correlation was also present between the 
RFC80 AA genotype and MTRR2756 AA. When samples were stratified according to CT gene 
expression, the correlation between RFC80 AA and MTRR2756 AA genotypes was only 
observed among CT(+) samples (Table 18). Among the CT(-) samples, the RFC80 “GG or GA” 
correlation with MTHFR1298 AA was observed, in addition to a novel negative correlation 
between MTRR66 GG and RFC80 GA (Table 18). 
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Table 18.  One carbon enzyme genotype associations in lung cancer patients 
  Correlation Coefficient (Spearman’s rho)  
Genotype 1 Genotype 2 All CT(+) CT(-) p* 
      
MTHFR677 CC MTRR66 GG -0.417 N.C.& N.C. 0.006 
      
MTHFR1298 AA MTRR66 GG -0.354 N.C N.C. 0.02 
      
MTHFR1298 AA RFC80 GG/GA 0.45 N.C. 0.482 0.001/0.01# 
      
MTRR2756 AA RFC80 AA 0.338 0.63 N.C. 0.02/0.001 
      
MTHFR677 CC RFC80 GG/GA 0.281 N.C. N.C. 0.05 
      
MTRR66 GG RFC80 GA N.C. N.C. -0.452 0.03 
      
*Fishers exact test (2-sided); &N.C.: no correlation; #p values correspond to the first and second 
correlation coefficients, respectively. 
 
 
3.6 Univariate power analysis of CT expression and one carbon enzyme genotype associations 
We then calculated the minimum sample size we would required to differenciate samples 
according to their CT gene expression status, if genotypes were studied as two groups. Using the 
Power and Precision software, we performed Wald’s test and a univariate logistic regression 
model. It is important to point out that the polymorphisms are analyzed independently, regardless 
of the effect of other variants studied. Our analysis revealed that as few as 80 samples would 
help us distinguish samples by their CT expression pattern if they were classified into MTFF66 
AA and “AG or GG” genotype groups. Similarly, including less than 200 samples in a 
prospective study is predicted to help distinguish samples according to their RFC80 as well as 
MTHFR677 polymorphisms (Table 19). It is important to point out that the polymorphisms are 
analyzed independently, regardless of the effect of other variants studied. 
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Table 19. Univariate power analysis* 
Genotype Event rates** Sample size 
   
MTRR66 AA vs. AG/GG 0.20 vs. 0.51 80 
   
RFC80GG vs. GA/AA 0.67 vs. 0.42 128 
   
MTHFR677 CC vs. CT/TT  0.29 vs. 0.51 159 
   
MTHFR1298 AA vs. AC/CC 0.56 vs. 0.41 352 
   
MTHFR2756 AA vs. AG/GG 0.45 vs. 0.50 3135 
   
* Logistic regression model, Wald’s test, α=0.05, power=80; **Probability of a sample being CT 
(+) for the given genotype 
 
 
3.7 Multivariate power analysis of CT expression and one carbon enzyme genotype 
associations 
The univariate power analysis model assumes that the distribution of genotypes of 
polymorphisms other than that for which the calculations are made occur at random frequencies. 
However, we already determined that genotypes co-exist among lung cancer samples, as well as 
within CT(+) and CT(-) groups, as explained above. We wanted to determine the minimal 
sample number that could distinguish CT (+) from CT(-) samples for a given genotype would be, 
if the others behaved similar to our observations. We, therefore, performed a multivariate power 
analysis for each genotype controlling for the others. The minimum sample sizes calculated are 
shown in Table 20. The beta variant in this table is defined as the logarithm of the odds ratio 
defined on page 47. Thus, the MTRR66 AA versus AG/GG genotype distribution has a 
coefficient of -1.43  and requires at least 132 samples to distinguish CT (+) and CT (-) samples, 
given the genotypes of other enzymes are held constant as indicated (Table 20) . The beta 
variant in this table is defined as the logarithm of the odds ratio defined on page 47. Thus, the 
MTRR66 AA versus AG/GG genotype distribution has a coefficient of -1.43  and requires at 
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least 132 samples to distinguish CT (+) and CT (-) samples, given the genotypes of other 
enzymes are held constant as indicated (Table 20) .  
Table 20.  Multivariate power analysis* 
Genotype Adjusting for Beta Sample size 
MTRR66 AA 
MTRR66 AG/GG 
MTHFR677=CC, MTHFR1298=AA, 
MTR2756=AA, RFC80=GG 
-1.43 132 
      
MTHFR677 CC 
MTHFR677 CT/TT 
MTHFR1298=AA, MTR2756=AA, 
MTRR66=AA, RFC80=GG 
1.02 162 
  
  
  
RFC80GG 
RFC80GA/AA 
MTHFR677=CC, MTHFR1298=AA, 
MTR2756=AA, MTRR66=AA 
1.03 165 
    
MTHFR1298 AA 
MTHFR1298 AC/CC 
MTHFR677=CC, MTR2756=AA, 
MTRR66=AA, RFC80=GG 
0.61 480 
      
MTHFR2756 AA 
MTHFR2756 AG/GG 
MTHFR677=CC, MTHFR1298=AA, 
MTRR66=AA, RFC80=GG 
-0.2 5253 
      
 
* Logistic regression model, Wald's test, α=0.05, power=80 
 
Note that there is a difference between the sample sizes found in the univariate and the 
multivariate tests. This finding constitutes the backbone of our study, which argues that it is 
important to study these alleles comprehensively in order to overcome the possibility of missing 
the effect of a polymorphism which is disregarded. 
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From the results derived from the multivariate analysis mentioned above, we have, with 
an 80% power, calculated the standard errors and p-values in the condition where the sample size 
is large enough to find a significant difference. For example, if we studied ≥132 samples, we 
would be able to distinguish the CT (+) and CT (-) lung cancer samples by testing for MTRR 66 
AA and AG/GG genotypes.  
These statistical analyses give us an idea about the size of the sample and the genotypes 
to be studied in our future experiments. For instance, since the MTR 2756 genotype requires 
5253 samples, it is very likely that we would not include the typing of this genotype in a larger 
epidemiologic study. Besides, we have observed that when the combined effects of the 
polymorphisms are taken into consideration, we obtain a different result when they are not 
collectively analyzed and this indicates the importance of studying these alleles collectively.  
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CHAPTER 4. DISCUSSION 
AND FUTURE PERSPECTIVES 
 
 The study conducted by Gure et al in 2005 revealed that CT genes were coordinately 
expressed and associated with poor prognosis [26]. Data from the same group and others showed 
that CT gene expression was primarily regulated by DNA methylation [24]. The outcome of 
these studies constituted the basis of the current study. S-adenosylmethionine is the one and only 
methyl donor in the cell and therefore it is likely that an event altering SAM production would 
affect CT expression. The polymorphisms in the one carbon pathway enzyme genes, which are 
thought to cause reductions in SAM production, have already been shown to correlate with DNA 
hypomethylation and increased SAH levels. Therefore, we decided to type lung cancer samples 
whose CT gene expression status had been identified previously for the one carbon pathway 
enzyme variants and check whether a given haplotype could predict the existence of CT 
expression so that further studies for silencing  the CT expression to improve the prognosis can 
be conducted.  
 In this study, the typing of the polymorphisms was conducted by the restriction fragment 
length polymorphism (RFLP) method. In order to verify our results, we tried to reproduce our 
data by a number of methods. While a total of 127 experiments were performed only once, 36 
experiments were repeated two times and 13 experiments were repeated three times or more. We 
found inconsistent results for a total of 9 samples.  18 samples within our lung cancer panel were 
re-typed by sequencing analysis. Besides the lung cancer samples, genomic DNA samples from 
cancer cell lines were also typed with the same method. A number of inconsistencies remain 
unresolved at presence. and are summarized in Table 21.   
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Table 21. Genotype typing inconsistencies 
Genotype/Allele Experiment 1  Experiment 2  
MTHFR 677    
Sample #726 C/T (RFLP) C/C (RFLP) 
Sample #745 C/T (RFLP) T/T (sequencing) 
Sample #639 C/T (RFLP) C/C (sequencing) 
MTRR 66   
Sample #693 A/A (RFLP) G/G (RFLP) 
RFC 80   
SKCO1 cell line A/A (RFLP) A/G (sequencing) 
  
 For the MTHFR C677T genotype, with the RFLP analysis, we observed contradictory 
results for 3 samples and typing with sequencing analysis generated inconsistent data for 2 out of 
the 5 samples. There were 5 findings which we were unable to re-obtain by RFLP analysis for 
the MTRR A66G polymorphism and 2 discordant results optained by sequencing for the RFC 
G80A variant. These samples remain to be further analyzed. 
The below experiment demonstrates and innate problem of RFLP, namely that 
incomplete enzymatic digestion can cause erroneous results (Figure 4). The indicated Lung 
cancer sampleswere subjected to Hinp1I digestion overnight, following PCR amplification. Lu-
183 DNA digestion generated a 154 bp band (as well as a smaller 124bp band not visible on the 
figure) and therefore was classified as a GG homozygote. Lu 191 is a heterozygote, and so is Lu 
726. However, despite the extended digestion time, Lu 718 and Lu 728 DNA digestion is most 
likely incomplete.If incomplete digestion took place for the other samples as well, we could be 
misinterpreting the results; for example all the above samples could be AA homozygotes. 
Despite several repeats Lu 726 typing remains unresolved.  
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Figure 4. RFPL analysis of RFC G80A polymorphism. 
 Consequently, these results require us to reproduce our data by a more reliable and 
ideally, a high-throughput method.  One dependable and relatively new technique for SNP 
analysis is the probe based real time quantitative polymerase chain reaction (Q-PCR) [72].  
 
Q-PCR allows quantification of polymorphic DNA regions and genotyping of single 
nucleotide polymorphisms in one run. The RFLP method, which involves 3 steps, requires the 
amplification of the region around a given SNP and digestion of the PCR product by a restriction 
enzyme with ensuing gel electrophoresis. However, with a single Q-PCR run, both quantification 
and genotyping can be performed simultaneously. Online monitoring of the amplification 
process as well as genotyping by melting curve analysis is possible by the use of hybridization 
probes. The hybridization probes are sequence-specific oligonucleotides labeled by fluorescence 
dyes. For the genotyping of the SNP, two hybridization probes are required. One covers the 
polymorphic region (sensor hybridization probe) and carries a florescent dye that emits green 
light. The second probe (the anchor probe) binds to a site close in proximity to the sensor 
hybridization probe and carries a red light emitting dye. During the amplification process, the 
hybridization probe anneals to the amplified DNA and emits green light, which then excites the 
red dye in the anchor probe. The energy transferred from the sensor probe to the anchor probe is 
called florescence resonance energy transfer (FRET). The FRET signal, which is detected by the 
Q-PCR machine, is a direct measure of the DNA copy.  
After amplification, the SNP’s can be detected by a melting-curve analysis. At this stage, 
the temperature is raised from 40oC to 75oC. Then, the temperature at which the hybridization 
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probes are melted off the DNA strand (Tm), which is an indicator of the presence or the absence 
of the mutation, is calculated. If the hybridization probe fits perfectly to the template DNA, then 
it will have a higher Tm. If there is a single nucleotide mismatch, then the probe will melt at a 
lower temperature. The melting curve analysis can yield three results. One is a curve with a 
single early peak, second is a curve with a single late peak, and the last one is a curve with two 
peaks. The results obtained by this method are quite reliable that the melting points for a specific 
SNP is always at the same point. However, if there is another SNP within the region of the 
hybridization probe binding site, then the melting points for each genotype will deviate. A 
deviation more than 1.5oC in the melting curve step, is an indication of an additional mutation 
within the binding region of the hybridization probe [73]. For instance, a recent study has shown 
that an additional mutation causes deviations in the detection of the MTHFR A1298C SNP [72]. 
An exemplary graph shows the possible alleles and an unexpected nearby mutation curves 
(Figure 5). Notice the heterozygote allele has a lower florescence value than the homozygote 
alleles. 
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Figure 5. An exemplary RT-PCR melting-curve analysis showing the possible genotypes with an additional 
unexpected mutation. 
 
Thus quantitative Q-PCR offers several advantages over RFLP, However, given the fact 
that there are a significantly large number of SNPs identified for each enzyme; sequencing 
analysis would offer further reliability. 
Despite the suggestion that enzyme digestion might be incomplete in a number of 
experiments of ours, another possible explanation that can explain variations of band intensities 
we consistently observed for some samples is that there might be a copy number variation 
(CNV) in the genes we studied. What directed us to this conclusion was that upon the digestion 
procedure of the MTRR 66 polymorphism, there was a greater intensity of the G allele than the 
A allele in some of the heterozygote samples. This is demonstrated in Figure 6. The figure 
demonstrates the RFLP results obtained for the MTRR A66G allele. The three bands obtained 
for Lu 706 is equal in intensity and correspond to bands expected for a heterozygote (66, 44 and 
22bp). The 44bp band is significantly more intense than the 66bp band. However, for Lu 706, 
713, 716 and 658, the 66bp band is significantly more intense than the 44bp and 22bp bands. It is 
unlikely that incomplete digestion accounts for these, because this experiment was repeated 4 
times with equal results. If alleles are amplified in the genome resulting in CNV, then the 
subsequent RFLP analysis would be expected to generate a result as shown in Figure 6. 
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Figure 6. A possible copy number variation in the MTRR A66G polymorphism. The “G” band is significantly 
more intense than the “A” band in the 2nd, 3rd, 4th and 5th lanes whereas the intensity is equal in the 1st lane. 
 
It is important to know whether there is a copy number variation (CNV) of these genes 
and this should be investigated by the Q-PCR method explained above or CNV microarray 
studies. The amplification step could reveal, the increase in the copy number of the one carbon 
pathway genes. If the presence of a copy number variation in the MTRR gene and in other genes 
is found, this possibly might have occurred towards the compensation of a reduced methyl group 
flow in the one carbon pathway. For instance, if the patient has a MTHFR 677 hypoactive allele 
(T), the cell could be amplifying the MTRR normoactive (C) allele in order to compensate for 
methionine synthesis through an increased activation of MTR, in the presence of low production 
of N5-methyl-THF caused by the MTHFR 677 T allele. Despite the fact that methionine 
synthesis is N5-methyl-THF – dependent, the amplification might still have a functional 
consequence. This could be novel a mechanism by which the cell maintains a specific rate of 
SAM production in the presence of certain mutations as there are no publications documenting 
CNV for these genes to date.  
Our analysis of the correlations between the 1 –carbon pathway enzyme genotypes and 
CT expression profiles of the lung cancer genomic DNA samples demonstrated important 
contradictions. First of all, we found out that the CT (-) tumor samples had a higher proportion of 
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the MTHFR 677 T allele when compared to the CT (+) samples (see Table 21, Chapter 3). This 
is difficult to reconcile with our hypothesis that the CT (+) samples have a higher proportion of 
this allele if their expression is due to inefficient SAM production. Moreover, despite not being 
statistically significant, 37.9% of the CT (-) were heterozygous for MTHFR 677, while only 
28.6% of CT (+) samples were heterozygous.  
In line with these results we also observed that for the MTRR A66G polymorphism. 
MTRR 66 GG allele, thought to code for the hypoactive enzyme, was present among CT (-) lung 
cancer samples at a rate that was five-fold more of what we observed for the CT (+) samples. As 
explained above, because we hypothesized that the CT (+) would have the greater frequency of 
hypoactive alleles, this data obtained appeared to be just the opposite of our initial hypothesis. 
Our data demonstrates a strong negative correlation between MTHFR 677 CC and 
MTRR 66 GG alleles,  normoactive variants of these two enzymes (MTHFR 677 CC and MTRR 
66 AG/AA); as well as between hypoactive variants (MTHFR 677 CT/TT and MTRR 66 GG). 
This would further suggest that among lung cancer patients, there are two haplotypes, one prone 
to efficient and the other prone to inefficient SAM production. Even though this is a plausible 
possibility, it makes it even more difficult to explain why the inefficient SAM producers should 
preferentially have CT (-) tumors. Therefore, I offer the following hypothesis that might possibly 
help understand this dilemma. 
It is known that SAM is used for the methylation of several substrates including RNA, 
DNA and proteins. Some of the most important substrates of SAM are, therefore the histone 
proteins. Histones are modified at specific residues in their N-terminal chains. These 
modifications include phosphorylation, sumoylation, acetylation, ubiquitination as well as 
methylation. The effect of each modification is being actively studied [74]. Methylation is one of 
the most critical modifications regulating of histone function. Mono, di- or tri- methylation of 
especially the 4th, 9th 27th and 79th lysine residues of H3 closely associate with repressed or 
activated chromatin [75]. It has been shown that the modifications associated with active 
chromatin include H3K4me2, HeK4me3, H3K36me3, while those associated with repressed 
chromatin include H3K4me1, H3K36me2, H3K9me1 and H3K79me1 {Li, 2007}.  
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Methylthioadenosine (MTA), a nucleoside produced in the polyamine biosynthetic 
pathway by the cleavage of SAM, is a known inhibitor of methyltransferases {Mato, 2007}. 
MTA has been shown to inhibit H3K4 methylation [76], [77] by inhibiting Set1 
methyltransferase [78]. In line with this observation, it has been shown that the addition of SAM 
to the RAW cell line inhibited LPS-induced TNF-α gene expression in vitro {Ara, 2008}. In the 
same study, it has also been observed by ChIP experiments that upon SAM treatment, H3K4 tri-
methylation is decreased compared to the LPS treated cells alone. H3K4 tri-methylation, as 
explained before, is a hallmark of transcriptional activation. It has also been found that the 
treatment of cells with SAM or MTA reduced the levels of H3K4me1 and H3K4me2, which 
suggested that these agents might be playing a role in inhibiting the enzyme responsible for the 
trimethylation of H3K4. Same observations were also obtained by a different study. Huang et al 
have observed that MTA decreased the levels of both H3K4me2 and H3K4me3 [78]. MTA is 
known to inhibit SAH hydrolase, the enzyme which converts SAH to homocysteine [79], and 
SAH itself is a strong competitive inhibitor of almost all SAM-dependent methyltransferases 
[82]. The SAH levels must be kept in check because many methyltransferases have a higher 
affinity for SAH than SAM, and this makes SAH, as just mentioned, a potent inhibitor of many 
methylation reactions [82]. 
Apart from affecting H3K4 methylation, MTA might also affects H3K9 methylation 
since it is known that the G9a, the H3K9 methyltransferase is a SAM-dependent 
methyltransferase. MTA, which reduces the level of H3K4 methylation, might also influence 
H3K9 methylation. In addition to this, Mutskov et al conducted a study in which they showed 
that H3K9 methylation can occur prior to DNA methylation [80]. 
Considering all of these observations, I have created a model in which CT expression is 
primarily regulated by histone modifications, which are affected by SAM concentrations.  
In this model, if the CT (-) lung cancer samples have a higher frequency of hypoactive 
alleles of MTHFR 677 and MTRR 66, resulting in less efficient SAM production when 
compared to CT (+) lung cancer samples. The inefficient production of SAM will yield 
decreased amounts of its metabolite, MTA. The decreased amount of MTA will allow H3K4 and 
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H3K9 methylations which in turn result in DNA methylation and the CT genes will be silenced 
(Figure 7). 
On the other side, the wild-type alleles of MTHFR 677 and MTRR 66 genes will result in 
an adequate production of SAM and consequently MTA. Because MTA is itself an inhibitor of 
methyltransferases and SAH hydrolase, SAH levels will increase. Since SAH is a strong 
inhibitor of almost all SAM dependent methyltransferases, along with MTA, they will have a 
suppressive effect on histone methylation. This would result in a reduction of H3K4 
trimethylation and H3K9 methylation. This will lead to disturbances in DNA methylation and 
CT expression since H3K9 will not be methylated (Figure 7).  
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Figure 7. Proposed model adopted from the results of this study for the regulation of CT genes 
 
 As a result, a new insight about CT gene expression could emerge. In order to test this 
model, we first have to start by checking whether different histone methyltransferases have the 
same sensitivity for SAM. This aspect of histone methyltransferases is important because 
different sensitivities would mean that they will respond to different SAM concentrations by 
distinct ways, which would eventually affect the activation/suppression of the target genes. There 
is a procedure of determining the enzymatic activity by a method called peptide methylation 
assay. In this assay described by Rathert et al [81], just like the procedure in ELISA experiments, 
the wells on the plate are coated with a target peptide. After the addition of the desired 
methyltransferases and SAM mixture into the wells, a continuous read-out of the reaction 
process is performed. As the methyltransferase methylates the target peptide, light of a certain 
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wavelength is emitted and the amount of light is read and quantified. The time versus emission 
graph will give us the kinetic activity of the enzyme. Then, ChIP experiments could be 
performed in a given haplotype to see whether the polymorphisms in the one carbon enzyme 
genes would have an effect on the histone modifications in CT genes. 
In order to regard the effect of these polymorphisms thoroughly, we have to focus on 
folic acid and DNA damage. As mentioned earlier, the deficiency of folic acid reduces the 
substrate flow for the MTHFR enzyme and the SAM production is impaired due to inefficient 
methionine production. Folic acid deficiency has been correlated with DNA hypomethylation. 
On the other hand, thymidylate synthase prevents uracil misincorporation by converting uracil 
into thymidine.  
Another possible mechanism for the explanation of a model which could explain our 
results belies on the assumption that different methyltransferases have different sensitivities to 
SAM. In this model, because CT (-) samples have more frequent mutant genotypes, the SAM 
production will be inefficient. If some methyltransferases are more sensitive to SAM 
concentrations than others, the histone proteins might be preferentially modified. For instance, if 
Set1, a H3K4 methyltransferase requires higher SAM concentrations for its optimum 
performance than Ga9, a H3K9 methyltransferase, then preferential downregulation of H3K4 
methylation, in low SAM concentrations, might result in a relatively high H3K9 methylation and 
thus, repression of gene transcription. On the other hand, in CT (+) samples generating adequate 
SAM concentrations, comparable H3K4- and H3K9-methyltransferase activities might result in 
preferential H3K4 tri-methylation resulting in gene activation. Figure 8 summarizes this model. 
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Figure 8. Proposed model for the regulation of CT genes adopted from the results of this study 
 
For a better understanding of CT gene regulation and the effect of one carbon pathway 
enzyme gene polymorphisms, we will pursue our studies by selecting two cell lines with a 
certain a genotype which we know is associated with CT positivity. Then, by culturing these cell 
lines in a folic acid deficient medium we’ll induce DNA damage. The DNA damage will be 
evaluated by using the comet assay method, which is used for the detection of single and double 
strand breaks on the DNA. The folic acid deficiency would result in decreased amounts of 5-
methylene-THF, which is a substrate for both MTHFR and TS. So, we would be able to see the 
difference between a MTHFR 677 CC and MTHFR 677 TT genotype for the utilization of the 5-
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methylene-THF in the methylation direction. The impaired MTHFR 677 TT genotypes are 
expected to have a lesser degree of DNA damage because the thymidylate synthase enzyme will 
have a larger amount of 5-methylene-THF for the conversion of dUMP to dTMP, preventing 
uracil misincorporation. Moreover, by the addition of SAM into the cell culture, the expression 
of CT genes will be observed.  
In our subsequent studies, we might also focus on the methyltransferases and the 
metabolism of SAM in order to further investigate the relationship between the production of 
SAM, MTA and histone modifications. For this reason, we have pursued a preliminary micro-
array meta analysis from data compiled from 17 independent datasets corresponding to 
microarray data obtained from different tumors.. Table 22 lists the genes which are significantly 
up or downregulated, the probes and the number of experiments along with the average fold 
change. 
Table 22. The microarray meta-analysis showing the average fold changes of gene expression for the listed genes 
in cancer. 
Gene Probe Direction Number of 
experiments 
Average Fold 
change 
TS 1 up 2 2.04 
TS 2 up 11 3.44 
MTR   down 5 1.53 
MTRR 1 down 4 1.77 
MTRR 2 up 1 1.84 
DHFR 1 up 2 1.67 
DHFR 2 up 7 1.92 
DHFR 3 up 6 1.96 
DHFR 4 up 5 1.78 
Methionine adenosyltransferase   up 5 1.96 
Adomet decarboxylase 1 up 7 2.68 
Adomet decarboxylase 2 up 5 1.92 
Spermine synthase   up 3 1.76 
Spermidine synthase   up 8 1.98 
Ornithine decarboxylase   up 10 2.67 
5’methyladenosine phosphorylase 1 up 1 1.65 
5’methyladenosine phosphorylase 2 up 1 1.52 
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It can be inferred from the Table 16 that different enzymes which we are not focused on 
might play important roles in SAM utilization and folate metabolism. The cancer cells may be 
upregulating these genes in order to compensate the deficiency of their substrates. Along with 
the thymidylate synthase expression data, obtained by Q-PCR, we can regard that different 
cancer cell lines have diverse TS expression values. For instance, the LS174T cell line has 
almost 6 times TS expression than the HCT15 cell line. These differences direct us to the one 
carbon pathway enzyme gene polymorphisms and the expression levels of methyltransferases of 
these two cell lines. These aspects of the pathway can be included in future studies. 
 
 
Figure 9. Q-PCR results showing the expression levels of thymidylate synthase in different cancer cell 
lines. 
 
Differential TS expression in different cell lines might indicate a mechanism to 
compensate for a hypoactive genotype of MTHFR 677 or severe DNA damage caused by uracil 
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misincorporation. Thus, as explained earlier [31], different cell lines might have distinct 
mechanisms to maintain an efficient SAM production and DNA synthesis rates. 
As a result, this study has shown that there might be a mechanistic bridge between the 
production of SAM and DNA methylation, which affects cancer-testis gene expression. The 
studies of folic acid intake, TS expression and activity should be pursued in order to regard their 
effects on SAM production and especially histone methyltransferases. This study has helped us 
gain new insight into the potential interplay between two mechanisms, the one carbon pathway 
and epigenetic modification, and has made it possible to envision the correct experiments that 
would be needed to elucidate this new aspect of CT gene regulation. 
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SUPPLEMENTARY FIGURES 
Table 23 (Supplementary Table 1). The genotype data of the CT (+) lung cancer patients 
Lu MTHFR C677T MTHFR A1298C MTR A2756G MTRR A66G RFC G80A 
31 CT AC AA AG AA 
68 CT AA AG GG AG 
87 CC AC AA GG GG 
89 CT AC AG AG AG 
111 CC AC AA AA GG 
131 CC AA AA AG GG 
168 CC AA AG AG AG 
185 CT AA AG AG AG 
186 CC AC AA AG GG 
219 CT AA AA GG GG 
223 TT AA AA GG AG 
649 CC CC AG GG AA 
652 CC AA AG AG AA 
658 CC AC AG AG AG 
726 CC AC AA AG AG 
736 CC AA AG AG AG 
739 TT AA AG GG AG 
745 CT AC AA GG GG 
752 CC AA AA AG AA 
753 CC AA AG AG AA 
759 CT AA AG AA AG 
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Table 24 (Supplementary Table 2). The genotype data of the CT (-) lung cancer patients 
Lu MTHFR C677T MTHFR A1298C MTR A2756G MTRR A66G RFC G80A 
69 CT AC AA GG AA 
77 TT AA AA AG GG 
88 CT AA AG GG GG 
90 CT AA AA AA AG 
108 CC AC AG AG AG 
110 CT CC AA GG AA 
112 CT AC AA GG AG 
180 CT AC AG AA AG 
183 CT AC AA AG AA 
191 CC AC AA AG AG 
221 TT AA AG GG GG 
225 CC AC AA AA AG 
639 CT AC AA   GG 
656 TT AA AA   GG 
670 TT AA AG AG AG 
692 CT AA AG   AG 
693 TT AC AG GG AG 
694 TT AC AG   AG 
698 CC AC AG AG AG 
706 CC AA AG   AA 
707 CT AC AG AG AA 
713 CC AC AG AG AG 
716 TT AC AG AG AG 
718 CT AA AA AA AG 
728 CC AC AA AA AG 
748 CT AA AA GG AG 
749 CC AA AA AG AG 
751 TT AA AA GG AG 
763 CC CC AA GG AA 
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Figure 10 (Supplementary Figure 1). RFLP results of the MTHFR C677T polymorphisms in lung cancer 
patients. 
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Figure 11 (Supplementary Figure 2). RFLP results of the MTHFR A1298C polymorphisms in lung cancer 
patients. 
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Figure 12 (Supplementary Figure 3). RFLP results of the MTR A2756G polymorphisms in lung cancer patients 
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Figure 13 (Supplementary Figure 4). RFLP results of the MTRR A66G polymorphisms in lung cancer 
patients. 
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Supplementary Figure 5. RFLP results of the RFC G80A polymorphisms in lung cancer patients. 
 
 
